Vernakalant mesaconine 4-triazole based specific tankyrase 1/2

4-triazole based specific tankyrase 1/2 inhibitor

is a small molecule inhibitor of polycomb repressive complex 1

C2HF3O2/c1-28(2)24-36(46-41(51)39(49)35(44)25-29-8-6-5-7-9-29)40(50)45-18-19-52-20-21-53-22-23-54-27-38(48)55-37-13-12-33-32-11-10-30-26-31(47)14-16-42(30

InChi: InChI=1S/C24H27FN2O4

CZC-25146 is a potent and selective LRRK2 inhibitor

Vernakalant mesaconine 4-triazole based specific tankyrase 1/2Vernakalant HCl, also known as RSD1235, is an investigational drug for the acute conversion of atrial fibrillation. Like other class III antiarrhythmics, vernakalant blocks atrial potassium channels, thereby prolonging repolarization. It differs from typical class III agents by blocking a certain type of potassium channel, the cardiac transient outward potassium current, with increased potency as the heart rate increases. This means that it is more